A Phase 1 interventional study of Romosozumab in Osteoporosis, sponsored by Amgen. Completed at 9 sites in United States. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 13th largest by enrollment, is one of 4 that started in 2012, is one of 3 in phase 1, and was the 2nd registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2012.
This study's enrollment of 60 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 25th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2012, is one of 5 in phase 1, and was the 20th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
Drug: Romosozumab
Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
Drug: Romosozumab
Administered by subcutaneous injection
Also known as: AMG 785, EVENITY™
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans of the lumbar spine (L1-L4) and analyzed by a central imaging lab.
Time frame: Baseline and day 85
Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.
Time frame: Baseline and day 85
Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.
Time frame: Baseline and day 85
Percent Change From Baseline in Serum Type-1 Aminoterminal Propeptide (P1NP)
Time frame: Baseline and days 4, 15, 29, 43, 57, 71, and 85
Percent Change From Baseline in Serum C-telopeptide (sCTX)
Time frame: Baseline and days 4, 15, 29, 43, 57, 71, and 85
Number of Participants With Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. A treatment-related adverse event (TRAE) was an adverse event assessed by the investigator as possibly related to the investigational product, indicated by a "yes" response to the question: Is there a reasonable possibility that the event may have been caused by the investigational product? A serious adverse event was defined as an adverse event that met at least 1 of the following serious criteria: * fatal, * life-threatening, * required in-patient hospitalization or prolongation of existing hospitalization, * resulted in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event.
Time frame: From first dose of study drug up to day 85
Number of Participants Who Developed Anti-romosozumab Antibodies
Two validated assays were used to detect the presence of anti-romosozumab antibodies. An electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Samples testing positive in the immunoassay were further tested in a competitive binding bioassay for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity, the participant was defined as positive for neutralizing antibodies. Participants who developed anti-romosozumab antibodies were those with a negative result at baseline and a positive result at any time postbaseline.
Time frame: Baseline and days 29, 57, and 85
Mean Serum Concentration of Romosozumab
Time frame: Days 4, 15, 29, 43, 57, 71 and 85
This study was conducted at 8 centers in the United States. The first participant enrolled on 30 March 2012 and the last participant enrolled on 21 August 2012.
| Milestone | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Started | 30 | 30 |
| Received treatment | 30 | 30 |
| Completed | 29 | 30 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans of the lumbar spine (L1-L4) and analyzed by a central imaging lab.
| percent change | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine | 2.13 ± 0.64 | 2.08 ± 0.63 |
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.
| percent change | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Femoral Neck | 2.06 ± 0.59 | 1.92 ± 0.58 |
Bone mineral density was assessed by dual energy X-ray absorptiometry (DXA) scans and analyzed by a central imaging lab.
| percent change | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density (BMD) at the Total Hip | 1.38 ± 0.34 | 1.40 ± 0.34 |
| percent change | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Day 4 | 22.1263 ± 3.3852 | 30.4935 ± 4.9950 |
| Day 15 | 140.9970 ± 15.1975 | 218.4994 ± 22.6148 |
| Day 29 | 128.3936 ± 17.7834 | 221.9954 ± 23.3718 |
| Day 43 | 164.1654 ± 17.7832 | 251.0495 ± 23.4572 |
| Day 57 | 99.3682 ± 14.9155 | 168.7689 ± 17.1565 |
| Day 71 | 127.4051 ± 14.8572 | 205.2619 ± 23.5171 |
| Day 85 | 64.9103 ± 10.5005 | 142.5601 ± 20.3233 |
| percent change | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Day 4 | -28.2149 ± 3.9352 | -14.8099 ± 4.6844 |
| Day 15 | -28.9365 ± 4.6974 | -22.2800 ± 5.1854 |
| Day 29 | 3.1008 ± 8.6448 | -1.8188 ± 7.4121 |
| Day 43 | 3.4511 ± 8.9913 | 11.0131 ± 10.0244 |
| Day 57 | 25.7433 ± 8.7440 | 35.7697 ± 13.5346 |
| Day 71 | 28.4465 ± 11.7345 | 44.3802 ± 13.7159 |
| Day 85 | 54.0549 ± 14.2140 | 61.1734 ± 13.9874 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. Laboratory value changes that required treatment or adjustment in current therapy were considered adverse events. A treatment-related adverse event (TRAE) was an adverse event assessed by the investigator as possibly related to the investigational product, indicated by a "yes" response to the question: Is there a reasonable possibility that the event may have been caused by the investigational product? A serious adverse event was defined as an adverse event that met at least 1 of the following serious criteria: * fatal, * life-threatening, * required in-patient hospitalization or prolongation of existing hospitalization, * resulted in persistent or significant disability/incapacity, * congenital anomaly/birth defect, and/or * other medically important serious event.
| Participants | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| All adverse events | 14 | 15 |
| Serious adverse events | 0 | 0 |
| AE leading to discontinuation of study drug | 0 | 0 |
| AE leading to discontinuation from study | 0 | 0 |
| Fatal adverse events | 0 | 0 |
| Treatment-related adverse events | 3 | 4 |
| Treatment-related serious adverse events | 0 | 0 |
| TRAE leading to discontinuation of study drug | 0 | 0 |
| TRAE leading to discontinuation from study | 0 | 0 |
| Treatment-related fatal adverse events | 0 | 0 |
Two validated assays were used to detect the presence of anti-romosozumab antibodies. An electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Samples testing positive in the immunoassay were further tested in a competitive binding bioassay for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity, the participant was defined as positive for neutralizing antibodies. Participants who developed anti-romosozumab antibodies were those with a negative result at baseline and a positive result at any time postbaseline.
| Participants | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Binding antibody positive | 2 | 2 |
| Neutralizing antibody positive | 0 | 0 |
| ng/mL | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| Day 4 | 15000 ± 6350 | 23200 ± 9730 |
| Day 15 | 10500 ± 3540 | 18500 ± 6640 |
| Day 29 | 3890 ± 2000 | 8200 ± 4470 |
| Day 43 | 14300 ± 4280 | 22800 ± 9390 |
| Day 57 | 5490 ± 2600 | 10700 ± 6380 |
| Day 71 | 13700 ± 5000 | 22700 ± 10500 |
| Day 85 | 5350 ± 3190 | 11600 ± 6850 |
Collected over From first dose of study drug up to day 85. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romosozumab 140 mg | — | 0/30 (0%) | 11/30 (36.7%) |
| Romosozumab 210 mg | — | 0/30 (0%) | 6/30 (20%) |
| Event | Romosozumab 140 mg | Romosozumab 210 mg |
|---|---|---|
| FatigueGeneral disorders | 3/30 | 0/30 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/30 | 1/30 |
| Injection site reactionGeneral disorders | 0/30 | 2/30 |
| Oedema peripheralGeneral disorders | 0/30 | 2/30 |
| NasopharyngitisInfections and infestations | 2/30 | 1/30 |
| Upper respiratory tract infectionInfections and infestations | 1/30 | 2/30 |
| ContusionInjury, poisoning and procedural complications | 2/30 | 1/30 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/30 | 0/30 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/30 | 0/30 |
| Age, Continuous(years) | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|
| Mean | 65.6 ± 7.5 | 66.7 ± 8.3 | 66.1 ± 7.8 |
| Age, Customized(Participants) | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|
| < 65 years | 14 | 15 | 29 |
| ≥ 65 years | 16 | 15 | 31 |
| Sex: Female, Male(Participants) | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|
| Female | 30 | 30 | 60 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 14 | 26 |
| Not Hispanic or Latino | 18 | 16 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Romosozumab 140 mg | Romosozumab 210 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 2 | 7 |
| Black (or African American) | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Other | 0 | 1 | 1 |
| White | 25 | 25 | 50 |
Ran from Mar 2012 to primary completion in Nov 2012, 7 months.
Results were first posted in Mar 2019, 6 years 3 months after primary completion.
Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab